Skip to main content

Table 1 Potential therapeutic agents for hepatocellular carcinoma by targeting LPCAT1’s regulatory network

From: LPCAT1 overexpression promotes the progression of hepatocellular carcinoma

Rank Cmap name Cell line Description Chemical formula Enrichment P Specificity Anti-cancer Anti-HCC
1 LY-294002 MCF7 Specific inhibitor of phosphatidylinositol 3-kinase C19H17NO3 − 0.437  < 0.0001 0.17
2 Trichostatin A PC3 Histone deacetylase 3 inhibitor C17H22N2O3 − 0.366  < 0.0001 0.53
3 Trichostatin A MCF7 C17H22N2O3 − 0.307  < 0.0001 0.67
4 Sirolimus MCF7 An immunosuppressant which possesses both antifungal and antineoplastic properties C51H79NO13 − 0.395  < 0.001 0.36
5 Tomatidine MCF7 / / − 0.982  < 0.001 0 /
6 Pyridoxine MCF7 The 4-methanol form of vitamin B6 C8H11NO3 − 0.981  < 0.001 0.01 /
7 Vorinostat MCF7 A drug currently under investigation for the treatment of cutaneous T cell lymphoma C14H20N2O3 − 0.673  < 0.01 0.28
8 Meticrane PC3 Diuretic medication C10H13NO4S2 − 0.976  < 0.01 0 / /
9 Harmine MCF7 / C13H12N2O − 0.972  < 0.01 0.01
10 Tanespimycin MCF7 A small molecule inhibitor of heat shock protein 90 (HSP90), which is developed for the treatment of several types of cancer, solid tumours or chronic myelogenous leukemia C31H43N3O8 − 0.305  < 0.01 0.49